

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

*This announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Company's shares will be made in the United States.*



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Sole Overall Coordinator, Placing Agent and Capital Market Intermediary



Reference is made to the announcement of Concord Healthcare Group Co., Ltd. (the "**Company**") dated 29 May 2025 in relation to the placing of 18,600,000 new H shares under the general mandate (the "**Placing Announcement**"). Capitalised terms used herein shall have the same meanings as those defined in the Placing Announcement unless otherwise specified.

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the Conditions set out in the Placing Agreement have been fulfilled and the Completion took place on 4 June 2025 in accordance with terms and conditions of the Placing Agreement. A total of 18,600,000 Placing Shares have been successfully placed by the Placing Agent to no fewer than six Placees at the Placing Price of HK\$5.38 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing approximately 7.54% of the number of issued H Shares and approximately 2.60% of the number of issued Shares immediately before the Completion, and approximately 7.01% of the number of issued H Shares and approximately 2.53% of the number of issued Shares as enlarged by the allotment and issue of the Placing Shares immediately upon the Completion as at the date of this announcement.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, (i) each of the Placees and their respective ultimate beneficial owner(s) (where applicable) is an Independent Third Party and not connected with the Company and its connected persons; and (ii) none of the Placees has become a substantial shareholder (as defined in the Listing Rules) of the Company upon the Completion.

The net proceeds from the Placing, after deducting the Placing commission and other relevant costs and expenses of the Placing, amounted to approximately HK\$93.94 million. The Company intends to apply the net proceeds from the Placing in the following manner: (a) approximately HK\$37.576 million or 40% will be used to fund the procurement of medical equipment, consumables, and pharmaceuticals for the medical institutions of the Company, which is expected to be fully utilized by 31 December 2025; (b) approximately HK\$28.182 million or 30% will be used to repay loans provided by financial institutions to the Company and its subsidiaries, including but not limited to principal and interest of working capital loans, principal and interest of fixed asset loans, and financing lease liabilities, which is expected to be fully utilized by 31 December 2025; and (c) approximately HK\$28.182 million or 30% will be used to supplement the working capital of the Company and its subsidiaries for general corporate purposes, which is expected to be fully utilized by 31 December 2025.

The Company will subsequently fulfil the corresponding filing procedures in respect of the Placing timely in accordance with relevant rules of the China Securities Regulatory Commission.

Please refer to the Placing Announcement for further details of the Placing.

EFFECTS OF THE PLACING ON SHAREHOLDING STRUCTURE OF THE COMPANY

The number of total issued Shares of the Company has increased from 716,338,416 Shares to 734,938,416 Shares upon the Completion of the Placing. The number of the total issued H Shares has increased from 246,551,024 H Shares to 265,151,024 H Shares upon the Completion of the Placing, and the number of Domestic Shares remains unchanged as to 469,787,392 Domestic Shares.

The table below sets forth the shareholding structure of the Company immediately before and upon the Completion:

	(i) Immediately before the Completion		(ii) Immediately after the Completion	
	<i>Number of Shares</i>	<i>Approximate percentage of total issued Shares (%)</i>	<i>Number of Shares</i>	<i>Approximate percentage of total issued Shares (%)</i>
Domestic Shares				
Core connected persons (<i>Note 1</i>)	403,385,744	56.31	403,385,744	54.89
Other Domestic Shareholders	66,401,648	9.27	66,401,648	9.03
Sub-total	469,787,392	65.58	469,787,392	63.92
H Shares				
Core connected persons (<i>Note 2</i>)	96,659,100	13.49	96,659,100	13.15
Placees	—	—	18,600,000	2.53
Other H Shareholders	149,891,924	20.92	149,891,924	20.40
Sub-total	246,551,024	34.42	265,151,024	36.08
Total	716,338,416	100.00	734,938,416	100.00

Notes:

1. This represents the sum of (i) 205,607,968 Domestic Shares that Dr. Yang Jianyu, our chairman of the Board, is deemed to be interested; (ii) 120,000,000 Domestic Shares that CICC Jiatai Phase II (Tianjin) Equity Investment Fund Partnership (Limited Partnership) (中金佳泰貳期(天津)股權投資基金合夥企業(有限合夥)) is interested; and (iii) 77,777,776 Domestic Shares that Ningbo Xinyu Jiahui Enterprise Management Co., Ltd. (寧波信鈺嘉慧企業管理有限公司) is interested.
2. This represents 96,659,100 H Shares that Dr. Yang Jianyu, our chairman of the Board, is deemed to be interested.
3. The sum of the shareholding percentage may not be equal to the total percentage due to rounding.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, 4 June 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.